1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hainan Haiyao Co., Ltd. Class A

Hainan Haiyao Co., Ltd. Class A

SSZSE:000566
4.19
CNY
+0.09
(+2.20%)
-0.40EPS
6.47BMarket Cap
Hainan Haiyao Co., Ltd. Class A
SZSE:000566
(Shenzhen Stock Exchange)

Recent

price

4.19

P/E

ratio

- -

div

yld

1.72%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.6
0.79
0.99
1.07
1.4
1.55
1.31
1.26
1.86
1.84
1.7
1.59
1.37
1.14
0.76
0.64
0.58
Revenue per Share
0.04
0.12
0.08
0.1
0.17
0.18
0.14
0.06
0.09
-0.12
-0.45
-1.2
0.01
-0.08
-1.18
-0.33
-0.38
Basic EPS, GAAP
-0.08
-0.02
-0.14
-0.1
-0.21
-0.03
-0.16
-0.17
-0.81
-0.5
-0.68
-0.24
-0.09
-0.08
-0.15
-0.05
- -
Free Cash Flow per Basic Share
0.02
0.03
0.06
0.08
0.11
0.12
0.1
0.28
0.32
0.22
0.16
0.13
0.13
0.11
0.09
0.08
0.07
Dividend per Share
0.51
1.33
1.41
1.5
1.64
2.1
4.06
3.63
3.45
3.34
2.77
1.66
1.67
1.59
0.4
0.06
-0.1
Book Value per Share
0.29
1.13
1.11
1.13
1.23
1.72
3.4
2.92
2.7
2.52
1.96
0.92
1.03
0.86
-0.4
-0.74
-0.9
Tangible Book Value per Share
1,014
914
966
988
987
1,085
1,176
1,444
1,329
1,326
1,297
1,297
1,297
1,297
1,297
1,297
1,298
Basic Weighted Avg Shares
613
722
951
1,052
1,385
1,678
1,544
1,825
2,472
2,445
2,200
2,059
1,779
1,479
991
831
756
Sales/Revenue/Turnover
14.38
13.83
11.55
13.63
19.04
17.81
19.52
11.19
12.8
-11.9
-20.26
-11.99
-0.06
-1.26
-20.27
-23.58
-31.78
Operating Margin (%)
19
25
31
43
47
55
84
101
115
131
305
176
153
158
178
193
- -
Depreciation Expense
40
105
77
94
163
195
165
87
120
-159
-580
-1,555
11
-106
-1,525
-430
-490
Net Income, GAAP
15.62
10.1
10.53
20.21
17.27
16.77
18.54
23.24
28.49
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
6.44
14.56
8.12
8.92
11.76
11.64
10.66
4.75
4.84
-6.51
-26.37
-75.54
0.59
-7.2
-153.95
-51.73
-64.74
Profit Margin (%)
-3
872
909
304
740
1,066
3,644
2,791
2,266
1,358
195
-1,163
-1,476
-1,228
-2,897
-2,800
-2,746
Working Capital
5
99
495
496
678
753
316
1,706
1,445
944
828
688
660
902
864
1,353
1,304
LT Debt
502
1,332
1,490
1,590
1,728
2,537
5,630
5,077
4,825
4,631
3,972
2,385
2,337
2,200
590
120
-106
Total Equity
5.97
7.42
3.3
3.83
5.6
5.68
2.25
1.04
1.27
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
6.46
9.52
5.74
6.08
9.28
8.92
4.72
3.22
4.23
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
9.61
12.04
5.7
6.52
10.47
9.96
4.26
1.68
2.53
-3.51
-14.21
-53.13
0.49
-5.04
-117.88
-141.66
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,612
1,688
1,692
LT Borrowings
1,352
1,409
1,304
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,297
1,297
1,297
Market Capitalization
9,276
7,058
6,474

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,237
1,382
1,272
Cash, Cash Equivalents & STI
525
636
577
Accounts Receivable, Net
277
283
263
Inventories
255
257
249
Total Current Liabilities
4,037
4,012
4,019
Payables & Accruals
- -
- -
- -
ST Debt
1,612
1,688
1,692
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-11.18%
-40.13%
-79.69%
Free Cash Flow
83.58%
-24.91%
-67.15%
Net Income, GAAP
22.08%
42.87%
-71.81%
Sales/Revenue/Turnover
-5.15%
-17.2%
-16.1%
Total Cash Common Dividend
11.3%
-13.33%
-12.76%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
363
230
211
186
991
2025
207
244
- -
191
831
2026
168
153
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.14
-0.07
-0.95
-1.18
2025
-0.05
-0.07
- -
-0.14
-0.33
2026
-0.06
-0.1
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.02
0.02
0.09
2025
0.02
0.02
- -
0.02
0.08
2026
0.02
0.02
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hainan Haiyao Co., Ltd. (000566.SZ) manufactures and sells pharmaceutical products and medical devices primarily in China and internationally; the company develops intermediates, active pharmaceutical ingredients (APIs), innovative chemical drugs, modern Chinese medicines, biological drugs, cellular immunity products, and high-end medical devices including cochlear implants. Its core offerings encompass antibiotic series such as meropenem crude, meropenem with sodium carbonate, ceftriaxone sodium, cefuroxime sodium, and cefotaxime sodium; gastrointestinal medication series for acute and chronic gastroenteritis, ulcerative colitis, and irritable bowel syndrome; anti-tumor medicine series including docetaxel injections for ovarian, breast, lung, and nasopharyngeal cancers; bulk drugs and intermediates supporting preparations; finished dosage forms like pills, tablet granules, tincture fluid extracts, powders, syrups, soft capsules, powder injections, and health foods; and vitamin C injections for scurvy and idiopathic methemoglobinemia. Founded in 1965 as Haikou Pharmaceutical Factory and listed on the Shenzhen Stock Exchange in 1994, Hainan Haiyao maintains headquarters in Haikou, Hainan Province, China, and operates through subsidiaries focused on research, production, and sales across domestic and export markets including Southeast Asia and Europe; it additionally provides internet medical treatment and medical services. In recent developments, the company completed a global strategic restructuring on March 24, 2020, with Xinxing Jihua Pharmaceutical, transitioning to a mixed ownership enterprise controlled by a central enterprise; its subsidiary received a generic drug evaluation approval for an antibacterial injection and supplementary approval for meropenem for injection; and in November 2024, Hainan Haiyao signed an initial joint venture contract with Haikou High-tech Zone Guoke Industry Holdings Co., Ltd. and Xenios AG (a Fresenius Group subsidiary) to develop ECMO supporting products like long-term and short-acting membrane oxygenators and arteriovenous intubation, with planned investment up to RMB 200 million to accelerate high-end medical device deployment.